Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_aa48a431ce250933eb0fdd7a1caf3f30 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-215 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-216 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-135 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7084 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7053 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0014 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-135 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-216 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-215 |
filingDate |
1993-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
1999-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_91aabcc7230d415c513132b0efae9766 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2e01e5cafa633eaac7cc1fb971df083e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2c79bd57d8309ce1e940f73d65a6e7c6 |
publicationDate |
1999-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
EP-0767659-B1 |
titleOfInvention |
Transdermal administration of oxybutynin |
abstract |
The present invention is directed to the transdermal administration of oxybutynin together with a suitable permeation enhancer. The invention includes a transdermal drug delivery device comprising a matrix adapted to be placed in oxybutynin- and permeation enhancer-transmitting relation with the skin site. The matrix contains sufficient amounts of a permeation enhancer and of oxybutynin, in combination, to continuously administer to the skin for a predetermined period of time the oxybutynin to provide an effective therapeutic result. The invention is also directed to a method for the transdermal administration of a therapeutically effective amount of oxybutynin together with a skin permeation-enhancing amount of a suitable permeation enhancer. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6773421-B2 |
priorityDate |
1992-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |